GlassScriptPhysician profile
Yoon C Nofsinger
NPI 1871569285
$10,205.60
in general payments reported to CMS, 2019-2025
25 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 90% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $351 · 2021: $1,223 · 2022: $1,976 · 2023: $1,484 · 2024: $1,750 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,067.28 |
| Education | $253.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,997.83 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,606.76 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,414.16 | 2019-2025 | |
| Optinose US, INC. | $868.70 | 2019-2025 | |
| Aerin Medical INC. | $847.13 | 2021-2024 | |
| Medical Device Business Services, INC. | $840.96 | 2022 | |
| Glaxosmithkline, LLC. | $800.22 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $366.22 | 2023-2025 | Ruconest |
| Phadia US INC. | $271.15 | 2019-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $196.37 | 2020-2023 | |
| Kaleo, INC. | $194.91 | 2019-2023 | Auvi-Q |
| Cochlear Americas | $126.92 | 2024 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Intersect Ent, INC. | $118.63 | 2019 | |
| Stryker Corporation | $96.15 | 2019 | |
| Medtronic USA, INC. | $91.12 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $72.01 | 2019-2022 | |
| Amgen INC. | $54.75 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $46.87 | 2019-2025 | |
| Itamar Medical INC | $32.92 | 2025 | Watchpatone |
| Smith+Nephew, INC. | $32.36 | 2019-2021 | |
| Alk-Abello, INC | $32.14 | 2021 | |
| Genentech USA, INC. | $29.62 | 2019 | |
| Medtronic, INC. | $29.31 | 2025 | Propel |
| Lilly USA, LLC | $21.87 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoon Nofsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.